Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12022152 | 0.98 | CYP19A1 (0.62) | CYP19A1NPC1RAB9AHDAC8HDAC6 | |
| SCHEMBL17697510 | 0.95 | CYP19A1 (0.58) | CYP19A1NPC1RAB9AHDAC8HDAC6 | |
| Bromide SCHEMBL1888885 | 0.89 | L3MBTL1 (0.59) | CYP19A1NPC1RAB9AHDAC8HDAC6 | |
| SCHEMBL12022150 | 0.88 | CYP19A1 (0.58) | CYP19A1NPC1RAB9AHDAC8HDAC6 | |
| Bromide SCHEMBL1889733 | 0.87 | HDAC8 (0.60) | CYP19A1NPC1RAB9AHDAC8HDAC6 | |
| Bromide SCHEMBL1883444 | 0.87 | HDAC8 (0.60) | CYP19A1NPC1RAB9AHDAC8HDAC6 | |
| Bromide SCHEMBL1881301 | 0.87 | HDAC8 (0.60) | CYP19A1NPC1RAB9AHDAC8HDAC6 | |
| Bromide SCHEMBL1890168 | 0.87 | HDAC8 (0.60) | CYP19A1NPC1RAB9AHDAC8HDAC6 | |
| SCHEMBL16206235 | 0.87 | CYP19A1 (0.70) | CYP19A1NPC1RAB9AHDAC8HDAC6 | |
| SCHEMBL9991081 | 0.87 | HDAC8 (0.60) | CYP19A1NPC1RAB9AHDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254871-B1 | SALTS COMPRISING ARYL-ALKYL-SUBSTITUTED IMIDAZOLIUM AND TRIAZOLIUM CATIONS AS IONIC FLUIDS | UNIV DRESDEN TECH (DE) | 2016-11-09 | — | — | EP | disclosed |
| US-9260397-B2 | Salts comprising aryl-alkyl-substituted imidazolium and triazolium cations and the use thereof | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2016-02-16 | — | — | US | disclosed |
| US-20110105761-A1 | Salts Comprising Aryl-Alkyl-Substituted Imidazolium and Triazolium Cations and the Use Thereof | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2254871-A1 | SALTS COMPRISING ARYL-ALKYL-SUBSTITUTED IMIDAZOLIUM AND TRIAZOLIUM CATIONS AS IONIC FLUIDS | Technische Universität Dresden (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009095012-A1 | SALTS COMPRISING ARYL-ALKYL-SUBSTITUTED IMIDAZOLIUM AND TRIAZOLIUM CATIONS AND THE USE THEREOF | Technische Universität Dresden (DE) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105761-A1 | Salts Comprising Aryl-Alkyl-Substituted Imidazolium and Triazolium Cations and the Use Thereof | RDX, HAX1, CHRM2 | CYP19A1 1138/4885NPC1 1145/4885RAB9A 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.